FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Srdan Verstovsek

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Physiology

Mutation

Co-author Network

Publications

TOP 3
Alfonso Quintás-Cardama; Jorge Cortes; Hagop Kantarjian; Sherry Pierce; Srdan Verstovsek
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
Paolo Strati; Jorge Cortes; Stefan Faderl; Hagop Kantarjian; Srdan Verstovsek
Long-Term Follow-Up of Patients With Hypereosinophilic Syndrome Treated With Alemtuzumab, an Anti-CD52 Antibody.
Paul Collier; Gregory Hollis; Reid Huber; Phillip C C Liu; Rajyalakshmi Luthra; Keyur Patel; Mark J Rupar; Srdan Verstovsek; Paul Waeltz; Timothy C Burn
Validation of Standards for Quantitative Assessment of JAK2 c.1849G>T (p.V617F) Allele Burden Analysis in Clinical Samples.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Srdan Verstovsek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alfonso Quintás-Cardama; Jorge Cortes; Hagop Kantarjian; Sherry Pierce; Srdan Verstovsek
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
Clinical lymphoma, myeloma & leukemia 2013;13(3):315-318.e2.
2013: Paolo Strati; Jorge Cortes; Stefan Faderl; Hagop Kantarjian; Srdan Verstovsek
Long-Term Follow-Up of Patients With Hypereosinophilic Syndrome Treated With Alemtuzumab, an Anti-CD52 Antibody.
Clinical lymphoma, myeloma & leukemia 2013;13(3):287-91.
2013: Paul Collier; Gregory Hollis; Reid Huber; Phillip C C Liu; Rajyalakshmi Luthra; Keyur Patel; Mark J Rupar; Srdan Verstovsek; Paul Waeltz; Timothy C Burn
Validation of Standards for Quantitative Assessment of JAK2 c.1849G>T (p.V617F) Allele Burden Analysis in Clinical Samples.
Genetic testing and molecular biomarkers 2013;17(5):429-37.
2013: Srdan Verstovsek; Elliott F Winton; Murat O Arcasoy; John V Catalano; Michael Deininger; John F Dipersio; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Jimmie H Harvey; Elizabeth Hexner; Richard S Levy; Roger M Lyons; Ruben A Mesa; Carole Miller; Ronald Paquette; Azra Raza; Victor Sandor; Richard T Silver; William Sun; Moshe Talpaz; Kris Vaddi; Hagop M Kantarjian
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
British journal of haematology 2013;161(4):508-16.
2013: Warren C Fiskus; Taghi Manshouri; Joseph P McGuirk; Karissa Peth; Jacqueline E Smith; Srdan Verstovsek; Sunil Abhyankar; Kapil N Bhalla
Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells.
Molecular cancer therapeutics 2013;12(5):577-88.
2013: Koichi Takahashi; Lynne Abruzzo; Jorge Cortes; Hagop Kantarjian; Sherry Pierce; Srdan Verstovsek
Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Leukemia research 2013;37(5):552-5.
2013: Alfonso Quintás-Cardama; Srdan Verstovsek
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(8):1933-40.
2013: Ruben A Mesa; Carole B Miller; Victor Sandor; Alan L Shields; Richard T Silver; William Sun; Moshe Talpaz; John V Catalano; Michael W Deininger; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Thomas Hare; Jimmie H Harvey; Hagop M Kantarjian; Richard S Levy; Elliott F Winton; Srdan Verstovsek
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(10):1285-92.
2013: Jason Gotlib; Karin Hartmann; Olivier Hermine; Hans-Peter Horny; Hanneke Kluin-Nelemans; Dean D Metcalfe; Alberto Orfao; Animesh Pardanani; Andreas Reiter; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Ayalew Tefferi; Cem Akin; Michel AROCK; Knut Brockow; Daniel J Deangelo; Luis Escribano; Tracy George; Srdan Verstovsek; Peter Valent
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.
Blood 2013;121(13):2393-401.
2013: Sa A Wang; Patricia M Miron; Guilin Tang; Srdan Verstovsek; Carlos E Bueso-Ramos; Su S Chen; Yang O Huh; Lloyd Hutchinson; Dan M Jones; L Jeffrey Medeiros; Roberto N Miranda
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
American journal of hematology 2013;88(3):219-24.
2013: Fabio P S Santos; Srdan Verstovsek
What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
Current opinion in hematology 2013;20(2):123-9.
2013: Srdan Verstovsek
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.
European journal of haematology 2013;90(2):89-98.
2013: Hun Ju Lee; Naval Daver; Hagop M Kantarjian; Srdan Verstovsek; Farhad Ravandi
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(2):327-35.
2013: Srdan Verstovsek
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Postgraduate medicine 2013;125(1):128-35.
2012: Rami S Komrokji; Srdan Verstovsek
Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
Expert review of hematology 2012;5(6):631-41.
2012: Ehab Atallah; Srdan Verstovsek
Emerging drugs for myelofibrosis.
Expert opinion on emerging drugs 2012;17(4):555-70.
2012: Preetesh Jain; Robert Z Orlowski; Srdan Verstovsek; Ernie Yap; Hesham M Amin
An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma.
Clinical lymphoma, myeloma & leukemia 2012;12(6):459-62.
2012: Fabio P S Santos; Srdan Verstovsek
JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
Anti-cancer agents in medicinal chemistry 2012;12(9):1098-109.
2012: Rami S Komrokji; Eric Padron; Srdan Verstovsek; Alan F List
Advances in the management of myelofibrosis.
Cancer control : journal of the Moffitt Cancer Center 2012;19(4 Suppl):4-15.
2012: Fabio P S Santos; Srdan Verstovsek
Therapy with JAK2 inhibitors for myeloproliferative neoplasms.
Hematology/oncology clinics of North America 2012;26(5):1083-99.
2012: Ohad Benjamini; Zeev Estrov; Preetesh Jain; Hagop M Kantarjian; Srdan Verstovsek
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
Blood 2012;120(13):2768-9.
2012: Priya Koppikar; Laura Leung; Omar Abdel-Wahab; Mazhar Adli; Bradley E Bernstein; Neha Bhagwat; Gabriela Chiosis; Benjamin L Ebert; Zeev Estrov; Aviva Goel; Mithat Gonen; Todd Hricik; Outi Kilpivaara; Fan Liu; Taghi Manshouri; Sachie Marubayashi; Ann Mullally; Stephen D Nimer; Lindsay M Saunders; Srdan Verstovsek; Abby Weinstein; Ross L Levine
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Nature 2012;489(7414):155-9.
2012: Alfonso Quintás-Cardama; Gautam Borthakur; Jorge Cortes; Zeev Estrov; Hagop Kantarjian; Srdan Verstovsek
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Leukemia research 2012;36(9):1124-7.
2012: Maro Ohanian; Srdan Verstovsek; Cameron Yin; Zeev Estrov; Yang Huh; Hagop Kantarjian; Vasiliki Leventaki; Pei Lin; Farhad Ravandi
Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity.
Leukemia & lymphoma 2012;53(9):1839-41.
2012: Srdan Verstovsek; Sherry Pierce; Ester Pungolino; Elisa Rumi; Deborah A Thomas; Gautam Borthakur; Domenica Caramazza; Mario Cazzola; Jorge E Cortes; Zeev Estrov; Elias Jabbour; Tapan Kadia; Hagop M Kantarjian; Enrica Morra; Francesco Passamonti
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Blood 2012;120(6):1202-9.
2012: Xiaodong Cheng; Emil J Freireich; Ming-Zhang Gao; Mirna Golemovic; Hagop M Kantarjian; Alfonso Quintás-Cardama; Michael Andreeff; Ralph Zingaro; Srdan Verstovsek
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
Anticancer research 2012;32(7):2871-80.
2012: Naveen Pemmaraju; Alfonso Quintas-Cardama; Farhad Ravandi; Jianqin Shan; Srdan Verstovsek; William Wierda; Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Jorge Cortes
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Haematologica 2012;97(7):1029-35.
2012: Alireza Eghtedar; Zeev Estrov; Stefan Faderl; Alessandra Ferrajoli; Solly George; Hagop M Kantarjian; Robert C Newton; Carol Bivins; Gautam Borthakur; Jan Burger; Jorge Cortes; Peggy A Scherle; Srdan Verstovsek; Farhad Ravandi
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Blood 2012;119(20):4614-8.
2012: Su-Jiang Zhang; Omar Abdel-Wahab; Mithat Gonen; Cyrus V Hedvat; Adriana Heguy; Todd Hricik; Hagop Kantarjian; Andrew Kayserian; Ross L Levine; Taghi Manshouri; Nana Mensah; Jay Patel; Raajit Rampal; Srdan Verstovsek
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
Blood 2012;119(19):4480-5.
2012: Claire Harrison; Mary F McMullin; Srdan Verstovsek; Ruben Mesa
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
British journal of haematology 2012;157(4):426-37.
2012: Fabio P S Santos; Srdan Verstovsek
Breakthroughs in myeloproliferative neoplasms.
Hematology (Amsterdam, Netherlands) 2012;17 Suppl 1():S55-8.
2012: Srdan Verstovsek; Elliott F Winton; Murat O Arcasoy; John V Catalano; Michael Deininger; John F DiPersio; Susan Erickson-Viitanen; Jason Gotlib; Vikas Gupta; Jimmie H Harvey; Elizabeth Hexner; Iphigenia L Koumenis; Richard S Levy; Roger M Lyons; Ruben A Mesa; Carole B Miller; Ronald Paquette; Azra Raza; Victor Sandor; Richard T Silver; William Sun; Moshe Talpaz; Kris Vaddi; Hagop M Kantarjian
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
The New England journal of medicine 2012;366(9):799-807.
2012: Alfonso Quintás-Cardama; Srdan Verstovsek
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Cancer 2012;118(4):870-7.
2012: Srdan Verstovsek
Ruxolitinib: the first agent approved for myelofibrosis.
Clinical advances in hematology & oncology : H&O 2012;10(2):111-3.
2012: Jasleen Randhawa; Ehab Atallah; Alen Ostojic; Radovan Vrhovac; Srdan Verstovsek
Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
Journal of hematology & oncology 2012;5():43.
2012: J Mascarenhas; T I Mughal; Srdan Verstovsek
Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.
Current medicinal chemistry 2012;19(26):4399-413.
2012: Alen Ostojic; Radovan Vrhovac; Srdan Verstovsek
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Therapeutics and clinical risk management 2012;8():95-103.
2011: Alfonso Quintás-Cardama; Nitin Jain; Srdan Verstovsek
Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.
Cancer 2011;117(24):5439-49.
2011: Warren C Fiskus; Kyungsoo Ha; Stacey L Hembruff; Taghi Manshouri; Joseph McGuirk; Nalabothula Narasimha Rao; Rekha Rao Manepalli; Jacqueline E Smith; Sreedhar Venkannagari; Srdan Verstovsek; Sunil Abhyankar; Ramesh Balusu; Kapil N Bhalla
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(23):7347-58.
2011: Alfonso Quintás-Cardama; Jianqin Shan; Srdan Verstovsek; Lynne V Abruzzo; Guillermo Garcia-Manero; Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Jorge Cortes
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.
Cancer 2011;117(22):5085-93.
2011: A Ostojic; R Vrhovac; Srdan Verstovsek
Ruxolitinib for the treatment of myelofibrosis.
Drugs of today (Barcelona, Spain : 1998) 2011;47(11):817-27.
2011: Ruben A Mesa; Animesh D Pardanani; Ayalew Tefferi; Deborah A Thomas; Kris Vaddi; Gautam Borthakur; Jorge Cortes; Amylou Dueck; Susan Erickson-Viitanen; Zeev Estrov; Hagop Kantarjian; Richard Levy; Srdan Verstovsek
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
Cancer 2011;117(21):4869-77.
2011: Dushyant Verma; Srdan Verstovsek; Elias Jabbour; Hagop Kantarjian; Susan O'Brien; Alfonso Quintas-Cardama; Farhad Ravandi; Mary Beth Rios; Sara S Strom; Jorge Cortes
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Blood 2011;118(16):4353-8.
2011: Jorge Cortes; Guillermo Garcia-Manero; Elias Jabbour; Susan O'Brien; Alfonso Quintas-Cardama; Farhad Ravandi; Jenny Shan; Srdan Verstovsek; Gautam Borthakur; Elizabeth Burton; Hagop Kantarjian
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Clinical lymphoma, myeloma & leukemia 2011;11(5):421-6.
2011: Alfonso Quintás-Cardama; Ying Zhang; Zeev Estrov; Amos Gaikwad; David Harris; Hagop M Kantarjian; Taghi Manshouri; Srdan Verstovsek
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Investigational new drugs 2011;29(5):818-26.
2011: Alen Ostojic; Radovan Vrhovac; Srdan Verstovsek
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Future oncology (London, England) 2011;7(9):1035-43.
2011: Kiran Naqvi; Hagop Kantarjian; Srdan Verstovsek; Farhad Ravandi
A potential role of ruxolitinib in leukemia.
Expert opinion on investigational drugs 2011;20(8):1159-66.
2011: Elias Jabbour; Hagop Kantarjian; Sherry Pierce; Deborah Thomas; Jorge Cortes; Lingsha Zhou; Srdan Verstovsek
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Blood 2011;118(4):899-902.
2011: Alfonso Quintás-Cardama; Srdan Verstovsek
New JAK2 inhibitors for myeloproliferative neoplasms.
Expert opinion on investigational drugs 2011;20(7):961-72.
2011: Carlos E Vigil; Sa A Wang; M James You; Roman Shinder; Srdan Verstovsek; Carlos Bueso-Ramos; Su S Chen; Jorge E Cortes; Bita Esmaeli; Ruth L Katz; Abha Khanna; John T Manning; Roberto N Miranda
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(17):e514-6.
2011: Fabio P S Santos; Srdan Verstovsek
JAK2 inhibitors: are they the solution?
Clinical lymphoma, myeloma & leukemia 2011;11 Suppl 1():S28-36.
2011: Jorge E Cortés; Emil J Freireich; Hagop Kantarjian; Srdan Verstovsek
Retrospect of hematologic malignancies 2010.
Clinical lymphoma, myeloma & leukemia 2011;11 Suppl 1():S1.
2011: Taghi Manshouri; Zeev Estrov; Alfonso Quintás-Cardama; Jan Burger; Ying Zhang; Ana Livun; Liza Knez; David Harris; Chad J Creighton; Hagop M Kantarjian; Srdan Verstovsek
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
Cancer research 2011;71(11):3831-40.
2011: Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'Brien; Elias Jabbour; Gautam Borthakur; Farhad Ravandi; Srdan Verstovsek; Jianqin Shan; Jorge Cortes
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Haematologica 2011;96(6):918-21.
2011: Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev Estrov; Srdan Verstovsek; Susan O'Brien; Stefan Faderl; Deborah A Thomas; John J Wright; Jorge Cortes
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Cancer 2011;117(6):1236-44.
2011: Srdan Verstovsek
Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(7):781-3.
2011: Fabio P S Santos; Srdan Verstovsek
JAK2 inhibitors: what's the true therapeutic potential?
Blood reviews 2011;25(2):53-63.
2011: Tiziano Barbui; Giovanni Barosi; Gunnar Birgegård; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben A Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(6):761-70.
2011: Meetu Agrawal; Ravin J Garg; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek; Alfonso Quintas-Cardama
Experimental therapeutics for patients with myeloproliferative neoplasias.
Cancer 2011;117(4):662-76.
2011: Stefan Faderl; Deborah Ann Thomas; Susan O'Brien; Farhad Ravandi; Guillermo Garcia-Manero; Gautam Borthakur; Alessandra Ferrajoli; Srdan Verstovsek; Mohamed Ayoubi; Michael Rytting; Jennie Feliu; Hagop M Kantarjian
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
Clinical lymphoma, myeloma & leukemia 2011;11(1):54-9.
2011: Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Nature reviews. Drug discovery 2011;10(2):127-40.
2011: Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Jody Hiteshew; Jenny Shan; Susan O'Brien; Hagop Kantarjian
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.
Cancer 2011;117(3):572-80.
2011: Aref Al-Kali; Hagop Kantarjian; Jianqin Shan; Roland Bassett; Alfonso Quintás-Cardama; Gautam Borthakur; Elias Jabbour; Srdan Verstovsek; Susan O'Brien; Jorge Cortes
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.
Cancer 2011;117(2):327-35.
2011: Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Haematologica 2011;96(1):62-8.
2011: Gloria N Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Koller; Sherry Pierce; Deborah Blamble; Stefan Faderl; Lianchun Xiao; Mike Hernandez; Hagop Kantarjian
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2011;19(1):19-26.
2010: Farhad Ravandi; Jorge Cortes; Stefan Faderl; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Fabio P S Santos; Jianqin Shan; Mark Brandt; Marcos De Lima; Sherry Pierce; Hagop Kantarjian
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.
Blood 2010;116(26):5818-23; quiz 6153.
2010: Aref Al-Kali; Srdan Verstovsek; Andrew Lamb; Rajyalakshmi Luthra; Jorge Cortes
Competing cell clones in myeloproliferative neoplasm.
Blood 2010;116(23):5074-5.
2010: Srdan Verstovsek; Andrew Lamb; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
The New England journal of medicine 2010;363(12):1117-27.
2010: Deborah A Thomas; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William G Wierda; Farhad Ravandi; Srdan Verstovsek; Jeffrey L Jorgensen; Carlos E Bueso-Ramos; Michael Andreeff; Sherry Pierce; Rebecca Garris; Michael J Keating; Jorge Cortes; Hagop M Kantarjian
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3880-9.
2010: Sameer A Parikh; Andrew Lamb; Aaron D Schimmer; William Walsh; Ekatherine Asatiani; Khaled El-Shami; Elliott Winton; Srdan Verstovsek
Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
Clinical lymphoma, myeloma & leukemia 2010;10(4):285-9.
2010: Effrosyni Apostolidou; Andrew Lamb; Deborah Thomas; Ian Burger; Gautam Borthakur; Srdan Verstovsek
Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Clinical lymphoma, myeloma & leukemia 2010;10(4):281-4.
2010: Mirna Golemovic; Alfonso Quintás-Cardama; Taghi Manshouri; Nada Orsolic; Hatice Duzkale; Mary Johansen; Emil J Freireich; Andrew Lamb; Ralph A Zingaro; Srdan Verstovsek
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
Investigational new drugs 2010;28(4):402-12.
2010: Jingxuan Pan; Chao Cheng; Srdan Verstovsek; Qi Chen; Yanli Jin; Qi Cao
The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells.
Cancer letters 2010;293(2):167-74.
2010: Matjaz Sever; Srdan Verstovsek; Jeremy Erasmus; Gloria N Mattiuzzi
Mycotic pulmonary artery aneurysm due to Aspergillus infection in a patient with leukemia: case report and review of the literature.
Leukemia research 2010;34(5):e133-6.
2010: Srdan Verstovsek
Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(7):1988-96.
2010: Stefan O Ciurea; Marcos De Lima; Sergio Giralt; Rima M Saliba; Carlos Bueso-Ramos; Borje S Andersson; Chitra M Hosing; Srdan Verstovsek; Richard E Champlin; Uday Popat
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(4):555-9.
2010: Alfonso Quintás-Cardama; Hesham M Amin; Andrew Lamb; Srdan Verstovsek
Treatment of aggressive systemic mastocytosis with daclizumab.
Leukemia & lymphoma 2010;51(3):540-2.
2010: Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Blood 2010;115(6):1131-6.
2010: Laura Millecker; Patrick A Lennon; Srdan Verstovsek; Bedia Barkoh; John Galbincea; Peter Hu; Su S Chen; Dan Jones
Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations.
Cancer genetics and cytogenetics 2010;197(1):1-7.
2010: Bo Feng; Srdan Verstovsek; Jeffrey L Jorgensen; Pei Lin
Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis.
American journal of clinical pathology 2010;133(2):314-20.
2010: Sameer A Parikh; Hagop M Kantarjian; Mary Ann Richie; Jorge E Cortes; Srdan Verstovsek
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.
Leukemia & lymphoma 2010;51(2):269-74.
2010: Omar Abdel-Wahab; Taghi Manshouri; Jay Patel; Kelly Harris; Jinjuan Yao; Cyrus V Hedvat; Adriana Heguy; Carlos Bueso-Ramos; Andrew Lamb; Ross Levine; Srdan Verstovsek
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Cancer research 2010;70(2):447-52.
2010: Ali Al Ameri; Charles Koller; Andrew Lamb; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Sherry Pierce; Gloria N Mattiuzzi
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Cancer 2010;116(1):93-7.
2010: Fabio P S Santos; Sergej N Konoplev; Huifang Lu; Srdan Verstovsek
Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia.
Leukemia research 2010;34(1):e35-7.
2009: Farhad Ravandi; Jean-Pierre J Issa; Guillermo Garcia-Manero; Susan O'Brien; Sherry Pierce; Jianqin Shan; Gautam Borthakur; Srdan Verstovsek; Stefan Faderl; Jorge Cortes; Andrew Lamb
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Cancer 2009;115(24):5746-51.
2009: Constantine S Tam; Andrew Lamb; Jorge Cortes; Alice Lynn; Sherry Pierce; Lingsha Zhou; Michael J Keating; Deborah A Thomas; Srdan Verstovsek
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(33):5587-93.
2009: Alfonso Quintás-Cardama; Andrew Lamb; Taghi Manshouri; Rajyalakshmi Luthra; Zeev Estrov; Sherry Pierce; Mary Ann Richie; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Srdan Verstovsek
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5418-24.
2009: Farhad Ravandi; Ahmed Aribi; Susan O'Brien; Stefan Faderl; Dan Jones; Alessandra Ferrajoli; Xuelin Huang; Sergernne York; Sherry Pierce; William G Wierda; Dimitrios Kontoyiannis; Srdan Verstovsek; Barbara Pro; Luis Fayad; Michael Keating; Andrew Lamb
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(32):5425-30.
2009: Matjaz Sever; Andrew Lamb; Sherry Pierce; Nitin Jain; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.
International journal of hematology 2009;90(4):522-5.
2009: Matjaz Sever; Jeffrey L Jorgensen; Inga Gurevich; Mariana Pinheiro; Srdan Verstovsek
Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient.
Leukemia research 2009;33(11):e186-8.
2009: Arturo Vega-Ruiz; Jorge E Cortes; Matjaz Sever; Taghi Manshouri; Alfonso Quintás-Cardama; Rajyalakshmi Luthra; Hagop M Kantarjian; Srdan Verstovsek
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
Leukemia research 2009;33(11):1481-4.
2009: Alfonso Quintás-Cardama; Hagop M Kantarjian; Taghi Manshouri; Deborah Thomas; Jorge Cortes; Farhad Ravandi; Guillermo Garcia-Manero; Alessandra Ferrajoli; Carlos E Bueso-Ramos; Srdan Verstovsek
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4760-6.
2009: Ayalew Tefferi; Srdan Verstovsek; Giovanni Barosi; Francesco Passamonti; Gail J Roboz; Heinz Gisslinger; Ronald L Paquette; Francisco Cervantes; Candido E Rivera; H Joachim Deeg; Juergen Thiele; Hans Michael Kvasnicka; James W Vardiman; Yanming Zhang; B Nebiyou Bekele; Ruben A Mesa; Robert P Gale; Hagop M Kantarjian
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4563-9.
2009: Dushyant Verma; Hagop M Kantarjian; Dan Jones; Rajyalakshmi Luthra; Gautam Borthakur; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Blood 2009;114(11):2232-5.
2009: Ruben A Mesa; Susan Schwager; Deepti Radia; Andrea Cheville; Kebede Hussein; Joyce Niblack; Animesh Pardanani; David P Steensma; Mark R Litzow; Candido E Rivera; John K Camoriano; Srdan Verstovsek; Jeffrey Sloan; Claire Harrison; Andrew Lamb; Ayalew Tefferi
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
Leukemia research 2009;33(9):1199-203.
2009: Apostolia-Maria Tsimberidou; Luis H Camacho; Srdan Verstovsek; Chaan Ng; David S Hong; Cynthia K Uehara; Catalina Gutierrez; Shawn Daring; Jan Stevens; Philip B Komarnitsky; Brian Schwartz; Razelle Kurzrock
A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(14):4769-76.
2009: Roberto H Nussenzveig; Jorge Cortes; Matjaz Sever; Alfonso Quintás-Cardama; Patricia Ault; Taghi Manshouri; Carlos Bueso-Ramos; Josef T Prchal; Andrew Lamb; Srdan Verstovsek
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
International journal of hematology 2009;90(1):58-63.
2009: Deborah A Thomas; Susan O'Brien; Jeffrey L Jorgensen; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Sherry Pierce; Yang Huh; William Wierda; Michael J Keating; Hagop M Kantarjian
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.
Blood 2009;113(25):6330-7.
2009: Nitin Jain; Jorge Cortes; Alfonso Quintás-Cardama; Taghi Manshouri; Rajyalakshmi Luthra; Guillermo Garcia-Manero; Andrew Lamb; Srdan Verstovsek
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
Leukemia research 2009;33(6):837-9.
2009: Carmen Fava; Hagop M Kantarjian; Elias Jabbour; Susan O'Brien; Nitin Jain; Mary Beth Rios; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Gautam Borthakur; Jianqin Shan; Jorge Cortes
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood 2009;113(21):5058-63.
2009: Ehab Atallah; Srdan Verstovsek
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Expert review of anticancer therapy 2009;9(5):663-70.
2009: Srdan Verstovsek
Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Leukemia research 2009;33(5):617-23.
2009: Constantine S Tam; Lynne V Abruzzo; Katherine I Lin; Jorge Cortes; Alice Lynn; Michael J Keating; Deborah A Thomas; Sherry Pierce; Andrew Lamb; Srdan Verstovsek
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
Blood 2009;113(18):4171-8.
2009: Elias Jabbour; Hagop M Kantarjian; Dan Jones; Jenny Shan; Susan O'Brien; Neeli Reddy; William G Wierda; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Blood 2009;113(10):2154-60.
2009: Elias Jabbour; Srdan Verstovsek
Treatment of myelofibrosis in younger patients: to transplant or not?
American journal of hematology 2009;84(3):131-2.
2009: Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Andrew Lamb
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):504-10.
2009: Srdan Verstovsek
Therapeutic potential of JAK2 inhibitors.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2009;():636-42.
2009: Effrosyni Apostolidou; Hagop M Kantarjian; Srdan Verstovsek
JAK2 inhibitors: A reality? A hope?
Clinical lymphoma & myeloma 2009;9 Suppl 3():S340-5.
2009: Srdan Verstovsek; Ayalew Tefferi; Andrew Lamb; Taghi Manshouri; Raja Luthra; Animesh Pardanani; Alfonso Quintás-Cardama; Farhad Ravandi; Patricia Ault; Carlos Bueso-Ramos; Jorge E Cortes
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):368-73.
2009: Malisha R Johnson; Srdan Verstovsek; Jeffrey L Jorgensen; Taghi Manshouri; Raja Luthra; Dan M Jones; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Yang O Huh
Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2009;22(1):50-7.
2009: Darko Antic; Srdan Verstovsek; Ivo Elezovic; Dana Grujicic; Mirjana Gotic; Jelena Bila; Maja Perunicic; Ljubomir Jakovic
Spinal epidural granulocytic sarcoma in non-leukemic patient.
International journal of hematology 2009;89(1):95-7.
2009: Wanlong Ma; Andrew Lamb; Xi Zhang; Chen-Hsiung Yeh; Zhong J Zhang; Srdan Verstovsek; Maher Albitar
Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
The Journal of molecular diagnostics : JMD 2009;11(1):49-53.
2009: Patricia Ault; Jorge Cortes; Alice Lynn; Michael Keating; Srdan Verstovsek
Pregnancy in a patient with hypereosinophilic syndrome.
Leukemia research 2009;33(1):186-7.
2008: Srdan Verstovsek
JAK2 inhibitors and myeloproliferative neoplasms.
Clinical advances in hematology & oncology : H&O 2008;6(12):878-80, 896.
2008: Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Xuelin Huang; Srdan Verstovsek; Farhad Ravandi; Zeev Estrov; Gautam Borthakur; Monica Kwari; Hagop M Kantarjian
Clofarabine combinations as acute myeloid leukemia salvage therapy.
Cancer 2008;113(8):2090-6.
2008: Constantine S Tam; Roberto M Nussenzveig; Uday Popat; Carlos E Bueso-Ramos; Deborah A Thomas; Jorge A Cortes; Richard E Champlin; Stefan E Ciurea; Taghi Manshouri; Sherry M Pierce; Hagop M Kantarjian; Srdan Verstovsek
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
Blood 2008;112(5):1628-37.
2008: Stefan Faderl; Farhad Ravandi; Xuelin Huang; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Gautam Borthakur; Srdan Verstovsek; Deborah A Thomas; Monica Kwari; Hagop M Kantarjian
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood 2008;112(5):1638-45.
2008: Wendy Stock; Samir D Undevia; Carol Bivins; Farhad Ravandi; Olatoyosi Odenike; Stefan Faderl; Elizabeth Rich; Gautam Borthakur; Lucy Godley; Srdan Verstovsek; Andrew Artz; William Wierda; Richard A Larson; Yanming Zhang; Jorge Cortes; Mark J Ratain; Francis Giles
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Investigational new drugs 2008;26(4):331-8.
2008: Srdan Verstovsek; Ayalew Tefferi; Jorge Cortes; Susan O'Brien; Guillermo Garcia-Manero; Animesh Pardanani; Cem Akin; Stefan Faderl; Taghi Manshouri; Deborah Thomas; Andrew Lamb
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3906-15.
2008: Taghi Manshouri; Alfonso Quintás-Cardama; Roberto H Nussenzveig; Amos Gaikwad; Zeev Estrov; Josef T Prchal; Jorge E Cortes; Hagop M Kantarjian; Srdan Verstovsek
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Cancer science 2008;99(6):1265-73.
2008: A Quintás-Cardama; W Tong; Andrew Lamb; D Thomas; Farhad Ravandi; S Kornblau; Taghi Manshouri; J E Cortes; Guillermo Garcia-Manero; Srdan Verstovsek
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Leukemia 2008;22(5):965-70.
2008: Fuad A El Rassi; Constantine S Tam; John Carwile; Srdan Verstovsek
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
Leukemia research 2008;32(5):821-2.
2008: Alfonso Quintás-Cardama; Antoine J Harb; Hesham M Amin; Srdan Verstovsek
Granulocytic sarcoma with massive scalp involvement.
American journal of hematology 2008;83(4):340-2.
2008: Andrew Lamb; Susan O'Brien; Jianqin Shan; Xuelin Huang; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi-Kashani; Srdan Verstovsek; Mary Beth Rios; Jorge Cortes
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Cancer 2008;112(4):837-45.
2008: Srdan Verstovsek; Taghi Manshouri; Alfonso Quintás-Cardama; David Harris; Jorge Cortes; Francis Giles; Andrew Lamb; Waldemar Priebe; Zeev Estrov
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):788-96.
2008: Giovanni Barosi; Ruben A Mesa; J Thiele; Francisco Cervantes; Peter J Campbell; Srdan Verstovsek; Brigitte Dupriez; Ross Levine; Francesco Passamonti; J Gotlib; John T Reilly; A M Vannucchi; C A Hanson; Lawrence Solberg; A Orazi; Ayalew Tefferi
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Leukemia 2008;22(2):437-8.
2008: Razelle Kurzrock; Hagop M Kantarjian; Michelle A Blascovich; Cindy Bucher; Srdan Verstovsek; John J Wright; Susan R Pilat; Jorge E Cortes; Elihu H Estey; Francis Giles; Miloslav Beran; Said M Sebti
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Ayalew Tefferi; Srdan Verstovsek; Animesh Pardanani
How we diagnose and treat WHO-defined systemic mastocytosis in adults.
Haematologica 2008;93(1):6-9.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Srdan Verstovsek
Treatment of systemic mastocytosis with denileukin diftitox.
American journal of hematology 2007;82(12):1124.
2007: Animesh Pardanani; Srdan Verstovsek
Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.
Cancer journal (Sudbury, Mass.) 2007;13(6):384-91.
2007: Elias Jabbour; Andrew Lamb; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Alessandra Ferrajoli; Stefan Faderl; Mary Ann Richie; Miloslav Beran; Francis Giles; Srdan Verstovsek
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Cancer 2007;110(9):2012-8.
2007: Elias Jabbour; Hagop M Kantarjian; Lynne V Abruzzo; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Jianqin Shan; Mary Beth Rios; Jorge Cortes
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood 2007;110(8):2991-5.
2007: Jorge Cortes; Elias Jabbour; George Q Daley; Susan O'Brien; Srdan Verstovsek; Alessandra Ferrajoli; Charles Koller; Yali Zhu; Paul Statkevich; Andrew Lamb
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cancer 2007;110(6):1295-302.
2007: Matko Kalac; Alfonso Quintás-Cardama; Radovan Vrhovac; Andrew Lamb; Srdan Verstovsek
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
Cancer 2007;110(5):955-64.
2007: Alfonso Quintás-Cardama; Srdan Verstovsek
Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera.
American journal of hematology 2007;82(9):859.
2007: Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegård; Ruben A Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Blood 2007;110(4):1092-7.
2007: Jingxuan Pan; Alfonso Quintás-Cardama; Taghi Manshouri; Jorge Cortes; Andrew Lamb; Srdan Verstovsek
Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406.
Cancer science 2007;98(8):1223-5.
2007: J Pan; Alfonso Quintás-Cardama; Taghi Manshouri; Francis Giles; P Lamb; Ayalew Tefferi; Jorge Cortes; Andrew Lamb; Srdan Verstovsek
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Leukemia 2007;21(7):1395-404.
2007: Amos Gaikwad; Srdan Verstovsek; Donghoon Yoon; Ko-Tung Chang; Taghi Manshouri; Roberto H Nussenzveig; Jorge Cortes; William Vainchenker; Josef T Prchal
Imatinib effect on growth and signal transduction in polycythemia vera.
Experimental hematology 2007;35(6):931-8.
2007: Ruben A Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T Reilly; Brigitte Dupriez; Ross Levine; Marie-Caroline Le Bousse-Kerdiles; Martha Wadleigh; Peter J Campbell; Richard T Silver; Alessandro M Vannucchi; H Joachim Deeg; Heinz Gisslinger; Deborah Thomas; Olatoyosi Odenike; Lawrence Solberg; Jason Gotlib; Elizabeth Hexner; Stephen D Nimer; Andrew Lamb; Attilio Orazi; James W Vardiman; Juergen Thiele; Ayalew Tefferi
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
Leukemia research 2007;31(6):737-40.
2007: Andrew Lamb; Susan O'Brien; Moshe Talpaz; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Francis Giles; Jorge Cortes
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Zeyu Xiong; Enli Liu; Yan Yan; Richard T Silver; Fan Yang; Irene H Chen; I Hodge; Srdan Verstovsek; F J Segura; Hong Wang; Josef T Prchal; Xiao-Feng Yang
A novel unconventional antigen MPD5 elicits anti-tumor humoral immune responses in a subset of patients with polycythemia vera.
International journal of immunopathology and pharmacology 2007;20(2):373-80.
2007: Steven M Kornblau; Deborah E Banker; Derek L Stirewalt; Danny Shen; Elizabeth Lemker; Srdan Verstovsek; Zeev Estrov; Stefan Faderl; Jorge Cortes; Miloslav Beran; C Ellen Jackson; Wenjing Chen; Elihu Estey; Frederick R Appelbaum
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Blood 2007;109(7):2999-3006.
2007: Alfonso Quintás-Cardama; Srdan Verstovsek
Is there still a role for interferon-alpha for newly diagnosed chronic myeloid leukemia in chronic phase?
Leukemia & lymphoma 2007;48(3):445-6.
2007: Yasuhiro Oki; Hagop M Kantarjian; Vazganush Gharibyan; Dan Jones; Susan O'Brien; Srdan Verstovsek; Jorge Cortes; Gail M Morris; Guillermo Garcia-Manero; Jean-Pierre J Issa
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Cancer 2007;109(5):899-906.
2007: Zeyu Xiong; Yan Yan; Enli Liu; Richard T Silver; Srdan Verstovsek; Fan Yang; Hong Wang; Josef T Prchal; Xiao-Feng Yang
Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.
Clinical immunology (Orlando, Fla.) 2007;122(3):279-87.
2007: Ruben A Mesa; Alfonso Quintás-Cardama; Srdan Verstovsek
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
Current hematologic malignancy reports 2007;2(1):25-33.
2007: Francis Giles; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Sherry Pierce; Maher Albitar; Jorge Cortes; Andrew Lamb
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British journal of haematology 2007;136(4):624-7.
2007: Maher Albitar; Julie M Vose; Marcella M Johnson; Kim-Anh Do; Amanda Day; Iman Jilani; Andrew Lamb; Michael Keating; Susan M O'Brien; Srdan Verstovsek; James O Armitage; Francis Giles
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Leukemia research 2007;31(2):139-45.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Zeev Estrov; Francis Giles; Anthony J Murgo; Nakia Ladie; Srdan Verstovsek; Jorge Cortes
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cancer 2007;109(2):248-55.
2007: Roberto H Nussenzveig; Sabina I Swierczek; Jaroslav Jelinek; Amos Gaikwad; Enli Liu; Srdan Verstovsek; Jaroslav F Prchal; Josef T Prchal
Polycythemia vera is not initiated by JAK2V617F mutation.
Experimental hematology 2007;35(1):32-8.
2007: Ruben A Mesa; Joyce Niblack; Martha Wadleigh; Srdan Verstovsek; John K Camoriano; Sunni Barnes; Angelina D Tan; Pamela J Atherton; Jeff A Sloan; Ayalew Tefferi
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
Cancer 2007;109(1):68-76.
2007: Jingxuan Pan; Alfonso Quintás-Cardama; Hagop M Kantarjian; Cem Akin; Taghi Manshouri; Peter Lamb; Jorge E Cortes; Ayalew Tefferi; Francis Giles; Srdan Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Blood 2007;109(1):315-22.
2006: Srdan Verstovsek; Alfonso Quintás-Cardama; Andrew Lamb; Ayalew Tefferi
Experimental therapy in myelofibrosis with myeloid metaplasia.
Expert opinion on investigational drugs 2006;15(12):1555-63.
2006: Srdan Verstovsek; Francis Giles; Alfonso Quintás-Cardama; Nichole Perez; Farhad Ravandi-Kashani; Miloslav Beran; Emil J Freireich; Andrew Lamb
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Hematological oncology 2006;24(4):181-8.
2006: Srdan Verstovsek; Francis Giles; Alfonso Quintás-Cardama; Taghi Manshouri; Ly Huynh; Paul Manley; Jorge Cortes; Ayalew Tefferi; Andrew Lamb
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Leukemia research 2006;30(12):1499-505.
2006: Francis Giles; Srdan Verstovsek; Stefan Faderl; Norbert Vey; Judith E Karp; Gail J Roboz; Khuda Dad Khan; Maureen Cooper; Syed Fazl Ali Bilgrami; Augustin Ferrant; S M G J Daenen; Verena Karsten; Ann Cahill; Maher Albitar; Andrew Lamb; Susan O'Brien; Eric Feldman
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia research 2006;30(12):1591-5.
2006: Guillermo Garcia-Manero; Hagop M Kantarjian; Blanca Sanchez-Gonzalez; Hui Yang; Gary Rosner; Srdan Verstovsek; Michael Rytting; William G Wierda; Farhad Ravandi; Charles Koller; Lianchun Xiao; Stefan Faderl; Zeev Estrov; Jorge Cortes; Susan O'Brien; Elihu Estey; Carlos E Bueso-Ramos; Jackie Fiorentino; Elias Jabbour; Jean-Pierre J Issa
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Blood 2006;108(10):3271-9.
2006: Srdan Verstovsek; Cem Akin; Taghi Manshouri; Alfonso Quintás-Cardama; Ly Huynh; Paul Manley; Ayalew Tefferi; Jorge Cortes; Francis Giles; Andrew Lamb
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Leukemia research 2006;30(11):1365-70.
2006: Zeyu Xiong; Enli Liu; Yan Yan; Richard T Silver; Fan Yang; Irene H Chen; Yangyang Chen; Srdan Verstovsek; Hong Wang; Josef T Prchal; Xiao-Feng Yang
An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(7):4907-16.
2006: Alfonso Quintas-Cardama; Andrew Lamb; Susan O'Brien; Elias Jabbour; Francis Giles; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Jianqin Shan; Srdan Verstovsek; Jorge Cortes
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Alfonso Quintas-Cardama; Ahmed Aribi; Jorge Cortes; Francis Giles; Andrew Lamb; Srdan Verstovsek
Novel approaches in the treatment of systemic mastocytosis.
Cancer 2006;107(7):1429-39.
2006: Elias Jabbour; Andrew Lamb; Dan Jones; Moshe Talpaz; Nebiyou Bekele; Susan O'Brien; Xian Zhou; Rajyalakshmi Luthra; Guillermo Garcia-Manero; Francis Giles; Mary Beth Rios; Srdan Verstovsek; Jorge Cortes
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia 2006;20(10):1767-73.
2006: Cecilia Arana-Yi; Alfonso Quintás-Cardama; Francis Giles; Deborah Thomas; Antonio Carrasco-Yalan; Jorge Cortes; Andrew Lamb; Srdan Verstovsek
Advances in the therapy of chronic idiopathic myelofibrosis.
The oncologist 2006;11(8):929-43.
2006: Karen W L Yee; Zhihong Zeng; Marina Konopleva; Srdan Verstovsek; Farhad Ravandi; Alessandra Ferrajoli; Deborah Thomas; William G Wierda; Efrosyni Apostolidou; Maher Albitar; Susan O'Brien; Michael Andreeff; Francis Giles
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5165-73.
2006: Tomislav Letilovic; Radovan Vrhovac; Srdan Verstovsek; Branimir Jaksic; Alessandra Ferrajoli
Role of angiogenesis in chronic lymphocytic leukemia.
Cancer 2006;107(5):925-34.
2006: Nada Orsolic; Mirna Golemovic; Alfonso Quintás-Cardama; Barbara Scappini; Taghi Manshouri; Joya Chandra; Ivan Basic; Francis Giles; Andrew Lamb; Srdan Verstovsek
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Cancer science 2006;97(9):952-60.
2006: Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Andrew Lamb
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Blood 2006;108(5):1497-503.
2006: Ayalew Tefferi; Jorge Cortes; Srdan Verstovsek; Ruben A Mesa; Deborah Thomas; Terra L Lasho; William J Hogan; Mark R Litzow; Jacob B Allred; Dan Jones; Catriona Byrne; Jerome B Zeldis; Rhett P Ketterling; Rebecca F McClure; Francis Giles; Hagop M Kantarjian
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Blood 2006;108(4):1158-64.
2006: Yasuhiro Oki; Jaroslav Jelinek; Miloslav Beran; Srdan Verstovsek; Hagop M Kantarjian; Jean-Pierre J Issa
Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.
Haematologica 2006;91(8):1147-8.
2006: W Ma; Andrew Lamb; Srdan Verstovsek; Iman Jilani; Mercedes Gorre; Francis Giles; J Cortes; S O'Brien; M Keating; Maher Albitar
Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
British journal of haematology 2006;134(3):341-3.
2006: Francis Giles; Srdan Verstovsek; Guillermo Garcia-Manero; Deborah Thomas; Farhad Ravandi; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Elias Jabbour; Jianqin Shan; Susan O'Brien; Maher Albitar; Andrew Lamb
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
British journal of haematology 2006;134(1):58-60.
2006: Karen W L Yee; Jorge Cortes; Alessandra Ferrajoli; Guillermo Garcia-Manero; Srdan Verstovsek; William G Wierda; Deborah Thomas; Stefan Faderl; Ivan King; Susan M O'Brien; Sima Jeha; Michael Andreeff; Ann Cahill; Mario Sznol; Francis Giles
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Leukemia research 2006;30(7):813-22.
2006: Stefan Faderl; Srdan Verstovsek; Jorge Cortes; Farhad Ravandi; Miloslav Beran; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Susan O'Brien; Charles Koller; Francis Giles; William G Wierda; Monica Kwari; Hagop M Kantarjian
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Francis Giles; William T Bellamy; Zeev Estrov; Susan M O'Brien; Srdan Verstovsek; Farhad Ravandi; Miloslav Beran; Paul Bycott; Yazdi K Pithavala; Heidi M Steinfeldt; Steven D Reich; Alan F List; Karen W L Yee
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Leukemia research 2006;30(7):801-11.
2006: Raoul Tibes; Michael J Keating; Alessandra Ferrajoli; William G Wierda; Farhad Ravandi; Guillermo Garcia-Manero; Susan O'Brien; Jorge Cortes; Srdan Verstovsek; Mary L Browning; Stefan Faderl
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Cancer 2006;106(12):2645-51.
2006: Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Srdan Verstovsek; Charles Koller; Stefan Faderl; Francis Giles; Alessandra Ferrajoli; William G Wierda; Shirley Odinga; Xuelin Huang; Deborah A Thomas; Emil J Freireich; Dan Jones; Michael J Keating; Hagop M Kantarjian
Eradication of minimal residual disease in hairy cell leukemia.
Blood 2006;107(12):4658-62.
2006: Alfonso Quintás-Cardama; Hagop M Kantarjian; Francis Giles; Srdan Verstovsek
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Seminars in thrombosis and hemostasis 2006;32(4 Pt 2):409-16.
2006: Deborah A Thomas; Francis Giles; Maher Albitar; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Susan M O'Brien; Guillermo Garcia-Manero; Michael J Keating; Sherry Pierce; Jerome B Zeldis; Hagop M Kantarjian
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer 2006;106(9):1974-84.
2006: Elihu Estey; Guillermo Garcia-Manero; Alessandra Ferrajoli; Stefan Faderl; Srdan Verstovsek; Dan Jones; Andrew Lamb
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Blood 2006;107(9):3469-73.
2006: Qi Liu; Luis Fayad; Fernando Cabanillas; Fredrick B Hagemeister; Gregory D Ayers; Mark Hess; Jorge Romaguera; Maria A Rodriguez; Apostolia-Maria Tsimberidou; Srdan Verstovsek; Anas Younes; Barbara Pro; Ming-Sheng Lee; Ana Ayala; Peter McLaughlin
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1582-9.
2006: Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos E Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Andrew Lamb
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Jorge E Cortes; Moshe Talpaz; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Hagop M Kantarjian
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Cancer 2006;106(6):1306-15.
2006: Joya Chandra; Jeannette Tracy; David Loegering; Karen Flatten; Srdan Verstovsek; Miloslav Beran; Mercedes Gorre; Zeev Estrov; Nicholas J Donato; Moshe Talpaz; Charles L Sawyers; Kapil N Bhalla; Judith E Karp; Edward A Sausville; Scott H Kaufmann
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
Blood 2006;107(6):2501-6.
2006: Yasuhiro Oki; Hagop M Kantarjian; Xian Zhou; Jorge Cortes; Stefan Faderl; Srdan Verstovsek; Susan O'Brien; Charles Koller; Miloslav Beran; B Nebiyou Bekele; Sherry Pierce; Deborah Thomas; Farhad Ravandi; William G Wierda; Francis Giles; Alessandra Ferrajoli; Elias Jabbour; Michael J Keating; Carlos E Bueso-Ramos; Elihu Estey; Guillermo Garcia-Manero
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2006: Elias Jabbour; Andrew Lamb; Susan O'Brien; Mary Beth Rios; Lynne V Abruzzo; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Blood 2006;107(2):480-2.
2006: Gloria N Mattiuzzi; Gladys Alvarado; Francis Giles; Luis Ostrosky-Zeichner; Jorge Cortes; Susan O'Brien; Srdan Verstovsek; Stefan Faderl; Xian Zhou; Issam I Raad; B Nebiyou Bekele; Gerhard J Leitz; Ivonne Lopez-Roman; Elihu H Estey
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrobial agents and chemotherapy 2006;50(1):143-7.
2005: Jaroslav Jelinek; Yasuhiro Oki; Vazganush Gharibyan; Carlos E Bueso-Ramos; Josef T Prchal; Srdan Verstovsek; Miloslav Beran; Elihu Estey; Hagop M Kantarjian; Jean-Pierre J Issa
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.
Blood 2005;106(10):3370-3.
2005: Farhad Ravandi; Susan O'Brien; Dan Jones; Susan Lerner; Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Guillermo Garcia-Manero; Deborah Thomas; Charles Koller; Srdan Verstovsek; Francis Giles; Jorge Cortes; Marco Herling; Andrew Lamb; Michael Keating
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: Francis Giles; Srdan Verstovsek; Deborah Thomas; Stanton Gerson; Jorge Cortes; Stefan Faderl; Alessandra Ferrajoli; Farhad Ravandi; Steven M Kornblau; Guillermo Garcia-Manero; Elias Jabbour; Susan O'Brien; Verena Karsten; Ann Cahill; Karen Yee; Maher Albitar; Mario Sznol; Andrew Lamb
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7817-24.
2005: Karen W L Yee; Anne Hagey; Srdan Verstovsek; Jorge Cortes; Guillermo Garcia-Manero; Susan M O'Brien; Stefan Faderl; Deborah Thomas; William G Wierda; Steven M Kornblau; Alessandra Ferrajoli; Maher Albitar; Evelyn McKeegan; David R Grimm; Toby Mueller; Rhonda R Holley-Shanks; Leonardo Sahelijo; Gary B Gordon; Hagop M Kantarjian; Francis Giles
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6615-24.
2005: Srdan Verstovsek; Mirna Golemovic; Andrew Lamb; Taghi Manshouri; Zeev Estrov; Paul Manley; Tong Sun; Ralph B Arlinghaus; Leila Alland; Margaret Dugan; Jorge Cortes; Francis Giles; Miloslav Beran
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Cancer 2005;104(6):1230-6.
2005: Elias Jabbour; Srdan Verstovsek; Francis Giles; Varsha Gandhi; Jorge Cortes; Susan O'Brien; William Plunkett; Guillermo Garcia-Manero; C Ellen Jackson; Andrew Lamb; Michael Andreeff
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Cancer 2005;104(3):541-6.
2005: Francis Giles; Susan O'Brien; Jorge Cortes; Srdan Verstovsek; Carlos E Bueso-Ramos; Jianqin Shan; Sherry Pierce; Guillermo Garcia-Manero; Michael Keating; Andrew Lamb
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Cancer 2005;104(3):547-54.
2005: Mirna Golemovic; Srdan Verstovsek; Francis Giles; Jorge Cortes; Taghi Manshouri; Paul W Manley; Jürgen Mestan; Margaret Dugan; Leila Alland; James D Griffin; Ralph B Arlinghaus; Tong Sun; Andrew Lamb; Miloslav Beran
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4941-7.
2005: Rashid Saba; Elias Jabbour; Francis Giles; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Emil J Freireich; Guillermo Garcia-Manero; Andrew Lamb; Srdan Verstovsek
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Cancer 2005;103(12):2551-7.
2005: Jean-Pierre J Issa; Vazganush Gharibyan; Jorge Cortes; Jaroslav Jelinek; Gail Morris; Srdan Verstovsek; Moshe Talpaz; Guillermo Garcia-Manero; Hagop M Kantarjian
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3948-56.
2005: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; Guillermo Garcia-Manero; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Gloria N Mattiuzzi; Apostolia-Maria Tsimberidou; Maher Albitar; Susan M O'Brien; Elihu Estey
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leukemia research 2005;29(6):649-52.
2005: Andrew Lamb; Moshe Talpaz; Susan O'Brien; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Jianqin Shan; Mary Beth Rios; Richard Champlin; Marcos De Lima; Jorge Cortes
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Jorge Cortes; Moshe Talpaz; Susan O'Brien; Dan Jones; Rajyalakshmi Luthra; Jianqin Shan; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Mary Beth Rios; Andrew Lamb
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2005: Alfonso Quintas-Cardama; Andrew Lamb; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Mary Beth Rios; Kimberly Hayes; Armand B. Glassman; B Nebiyou Bekele; Xian Zhou; Jorge Cortes
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Blood 2005;105(6):2281-6.
2005: Bryan T. J. Hennessy; Deborah A Thomas; Francis Giles; Andrew Lamb; Srdan Verstovsek
New approaches in the treatment of myelofibrosis.
Cancer 2005;103(1):32-43.
2004: Bryan T. J. Hennessy; Francis Giles; Jorge Cortes; Susan O'Brien; Alessandra Ferrajoli; Gladys Ossa; Guillermo Garcia-Manero; Stefan Faderl; Andrew Lamb; Srdan Verstovsek
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
American journal of hematology 2004;77(3):209-14.
2004: Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Rajyalakshmi Luthra; Francis Giles; Srdan Verstovsek; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Dan Jones; Moshe Talpaz
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Deborah A Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Srdan Verstovsek; Alessandra Ferrajoli; Charles Koller; Miloslav Beran; Sherry Pierce; Chul Ha; Fernando Cabanillas; Michael J Keating; Andrew Lamb
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Blood 2004;104(6):1624-30.
2004: Srdan Verstovsek; Zeev Estrov
Arsenic derivatives as therapeutic agents for hematologic malignancies.
Leukemia research 2004;28(9):901-3.
2004: Srdan Verstovsek; Francis Giles; Susan O'Brien; Stefan Faderl; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.
Leukemia research 2004;28(7):707-11.
2004: Deborah A Thomas; Stefan Faderl; Jorge Cortes; Susan O'Brien; Francis Giles; Steven M Kornblau; Guillermo Garcia-Manero; Michael J Keating; Michael Andreeff; Sima Jeha; Miloslav Beran; Srdan Verstovsek; Sherry Pierce; Laurie Letvak; August Salvado; Richard Champlin; Moshe Talpaz; Andrew Lamb
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Francis Giles; Deborah Thomas; Guillermo Garcia-Manero; Stefan Faderl; Jorge Cortes; Srdan Verstovsek; Alessandra Ferrajoli; Sima Jeha; Miloslav Beran; Charles Koller; Michael Andreeff; Ann Cahill; Caroline Clairmont; Mario Sznol; Andrew Lamb
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2908-17.
2004: Amit Panwalkar; Srdan Verstovsek; Francis Giles
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies.
Cancer 2004;100(8):1578-89.
2004: Andrew Lamb; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Francis Giles; Mary Beth Rios; Jianqin Shan; Laurie Letvak; Deborah Thomas; Stefan Faderl; Alessandra Ferrajoli; Jorge Cortes
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: Maha M T El-Zimaity; Andrew Lamb; Moshe Talpaz; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Srdan Verstovsek; Deborah Thomas; Alessandra Ferrajoli; Kimberly Hayes; B Nebiyou Bekele; Xian Zhou; Mary B Rios; Armand B. Glassman; Jorge E Cortes
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
British journal of haematology 2004;125(2):187-95.
2004: Barbara Scappini; Simona Gatto; Francesco Onida; Clara Ricci; Vladimir Divoky; William G Wierda; Michael Andreeff; Li Dong; Kimberly Hayes; Srdan Verstovsek; Hagop M Kantarjian; Miloslav Beran
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Cancer 2004;100(7):1459-71.
2004: Francis Giles; Martin S Tallman; Guillermo Garcia-Manero; Jorge E Cortes; Deborah A Thomas; William G Wierda; Srdan Verstovsek; Marta Hamilton; Emma Barrett; Maher Albitar; Hagop M Kantarjian
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Cancer 2004;100(7):1449-58.
2004: Nada Orsolic; Francis Giles; Henriette Gourdeau; Mirna Golemovic; Miloslav Beran; Jorge Cortes; Emil J Freireich; Andrew Lamb; Srdan Verstovsek
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
British journal of haematology 2004;124(6):727-38.
2004: Amit Panwalkar; Srdan Verstovsek; Francis Giles
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Cancer 2004;100(4):657-66.
2004: Andrew Lamb; Susan O'Brien; Jorge Cortes; Francis Giles; Jianqin Shan; Mary Beth Rios; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; William G Wierda; Steven M Kornblau; Alessandra Ferrajoli; Michael Keating; Moshe Talpaz
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; William G Wierda; Michael Keating; Moshe Talpaz
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Apostolia-Maria Tsimberidou; Elihu Estey; Jorge E Cortes; Guillermo Garcia-Manero; Stefan Faderl; Srdan Verstovsek; Deborah A Thomas; Alessandra Ferrajoli; Michael J Keating; Susan O'Brien; Hagop M Kantarjian; Francis Giles
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Francis Giles; Eric J Feldman; Gail J Roboz; Richard A Larson; Steven W Mamus; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Moshe Talpaz; Miloslav Beran; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia research 2003;27(12):1091-6.
2003: Francis Giles; Paula M Fracasso; Hagop M Kantarjian; Jorge E Cortes; Randy A Brown; Srdan Verstovsek; Yesid Alvarado; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Lisa P Wright; Tom Samson; Ann Cahill; Paula Lambert; William Plunkett; Mario Sznol; John F DiPersio; Varsha Gandhi
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Iman Jilani; Susan O'Brien; Taghi Manshuri; Deborah A Thomas; Vilmos A Thomazy; Maha Imam; Sana Naeem; Srdan Verstovsek; Andrew Lamb; Francis Giles; Michael Keating; Maher Albitar
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
Blood 2003;102(10):3514-20.
2003: Elihu H Estey; Peter F Thall; Xuemei Wang; Srdan Verstovsek; Jorge Cortes; Hagop M Kantarjian
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
Blood 2003;102(9):3097-9.
2003: Andrew Lamb; Susan O'Brien; Jorges Cortes; Jianqin Shan; Francis Giles; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Mary Beth Rios; Moshe Talpaz
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Cancer 2003;98(7):1430-7.
2003: Apostolia-Maria Tsimberidou; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Maher Albitar; Andrew Lamb; Elihu Estey; Francis Giles
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leukemia research 2003;27(10):893-7.
2003: Andrew Lamb; Varsha Gandhi; Jorge Cortes; Srdan Verstovsek; Min Du; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Susan O'Brien; Sima Jeha; Jan Davis; Zeev Shaked; Adam Craig; Michael Keating; William Plunkett; Emil J Freireich
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Blood 2003;102(7):2379-86.
2003: Apostolia-Maria Tsimberidou; Dawn E Colburn; Mary Alma Welch; Jorge E Cortes; Srdan Verstovsek; Susan M O'Brien; Maher Albitar; Hagop M Kantarjian; Francis Giles
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Cancer chemotherapy and pharmacology 2003;52(3):229-34.
2003: Simona Gatto; Barbara Scappini; Lan V Pham; Francesco Onida; Michele Milella; Greg Ball; Clara Ricci; Vladimir Divoky; Srdan Verstovsek; Hagop M Kantarjian; Michael J Keating; Jorge E Cortes-Franco; Miloslav Beran
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Haematologica 2003;88(8):853-63.
2003: Francis Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: Srdan Verstovsek; Scott Lunin; Andrew Lamb; Taghi Manshouri; Stefan Faderl; Jorge Cortes; Francis Giles; Maher Albitar
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
Leukemia research 2003;27(7):661-9.
2003: Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Guillermo Garcia-Manero; Mary Beth Rios; Stefan Faderl; Srdan Verstovsek; Alessandra Ferrajoli; Emil J Freireich; Moshe Talpaz; Andrew Lamb
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Blood 2003;102(1):83-6.
2003: Guillermo Garcia-Manero; Moshe Talpaz; Francis Giles; Jorge Cortes; Stefan Faderl; Susan O'Brien; Deborah Thomas; Srdan Verstovsek; Mary Beth Rios; Jianquin Shan; Alessandra Ferrajoli; William G Wierda; Hagop M Kantarjian
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Nada Orsolić; Lidija Sver; Srdan Verstovsek; Svjetlana Terzić; Ivan Basić
Inhibition of mammary carcinoma cell proliferation in vitro and tumor growth in vivo by bee venom.
Toxicon : official journal of the International Society on Toxinology 2003;41(7):861-70.
2003: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Elihu Estey; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; D A Thomas; Guillermo Garcia-Manero; Alessandra Ferrajoli; John T Manning; Michael J Keating; Maher Albitar; Susan O'Brien; Francis Giles
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia 2003;17(6):1100-3.
2003: Elihu Estey; Francis Giles; Jorge Cortes; Miloslav Beran; Srdan Verstovsek; Guillermo Garcia-Manero; Stefan Faderl; Andrew Lamb
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
Leukemia research 2003;27(6):475-9.
2003: Francis Giles; B Nebiyou Bekele; Susan O'Brien; Jorge E Cortes; Srdan Verstovsek; Maria Balerdi; Marwan Yared; Xian Zhou; Hagop M Kantarjian; Michael J Keating; Peter F Thall; Maher Albitar
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
British journal of haematology 2003;121(4):578-85.
2003: Hatice Duzkale; Iman Jilani; Nada Orsolic; Ralph A Zingaro; Mirna Golemovic; Francis Giles; Andrew Lamb; Maher Albitar; Emil J Freireich; Srdan Verstovsek
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines.
Cancer chemotherapy and pharmacology 2003;51(5):427-32.
2003: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Deborah A Thomas; Alessandra Ferrajoli; Susan O'Brien; J Kyle Wathen; Lian-Chun Xiao; Donald A Berry; Elihu H Estey
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Andrew Lamb; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Kevin White; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; William G Wierda; Steven M Kornblau; Jorge Cortes
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;97(9):2225-8.
2003: Srdan Verstovsek; Taghi Manshouri; Franklin O Smith; Francis Giles; Jorge Cortes; Elihu Estey; Andrew Lamb; Michael Keating; Sima Jeha; Maher Albitar
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
Cancer 2003;97(9):2212-7.
2003: Stefan Faderl; Deborah A Thomas; Susan O'Brien; Guillermo Garcia-Manero; Hagop M Kantarjian; Francis Giles; Charles Koller; Alessandra Ferrajoli; Srdan Verstovsek; Barbara Pro; Michael Andreeff; Miloslav Beran; Jorge Cortes; William G Wierda; Ngoc Tran; Michael J Keating
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Jorge Cortes; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Alessandra Ferrajoli; William G Wierda; Yesid Alvarado; Susan M O'Brien; Maher Albitar; Michael J Keating; Francis Giles
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2003;97(7):1711-20.
2003: Apostolia-Maria Tsimberidou; Elihu Estey; Jorge Cortes; Deborah Thomas; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Michael Keating; Maher Albitar; Susan O'Brien; Andrew Lamb; Francis Giles
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Cancer 2003;97(6):1481-7.
2003: Gloria N Mattiuzzi; Jorge E Cortes; Moshe Talpaz; James M Reuben; Mary Beth Rios; Jianjin Shan; Dimitrios P Kontoyiannis; Francis Giles; Issam Raad; Srdan Verstovsek; Alessandra Ferrajoli; Hagop M Kantarjian
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):976-80.
2003: Srdan Verstovsek; Andrew Lamb; Taghi Manshouri; Jorge Cortes; Stefan Faderl; Francis Giles; Michael Keating; Maher Albitar
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
Cancer 2003;97(5):1248-52.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis Giles; Mary Beth Rios; Stefan Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Yesid Alvarado; Jorge Cortes; Srdan Verstovsek; Deborah Thomas; Stefan Faderl; Zeev Estrov; Andrew Lamb; Francis Giles
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
Cancer chemotherapy and pharmacology 2003;51(1):81-6.
2002: Clara Ricci; Barbara Scappini; Vladimir Divoky; Simona Gatto; Francesco Onida; Srdan Verstovsek; Hagop M Kantarjian; Miloslav Beran
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Cancer research 2002;62(21):5995-8.
2002: Alvaro Aguayo; Hagop M Kantarjian; Elihu H Estey; Francis Giles; Srdan Verstovsek; Taghi Manshouri; Christy Gidel; Susan O'Brien; Michael J Keating; Maher Albitar
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Srdan Verstovsek; Elihu Estey; Taghi Manshouri; Francis Giles; Jorge Cortes; Miloslav Beran; Anna Rogers; Michael Keating; Andrew Lamb; Maher Albitar
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
British journal of haematology 2002;118(1):151-6.
2002: Barbara Scappini; Francesco Onida; Hagop M Kantarjian; Li Dong; Srdan Verstovsek; Michael J Keating; Miloslav Beran
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Cancer 2002;94(10):2653-62.
2002: Srdan Verstovsek; Hui Lin; Andrew Lamb; Giuseppe Saglio; Daniela De Micheli; Fabrizio Pane; Guillermo Garcia-Manero; Mariano Intrieri; Bruno Rotoli; Francesco Salvatore; Jie Qiang Guo; Moshe Talpaz; Giorgina Specchia; Giovanni Pizzolo; Anna Marina Liberati; Jorge Cortes; Robert C Quackenbush; Ralph B Arlinghaus
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.
Cancer 2002;94(9):2416-25.
2002: Srdan Verstovsek; Andrew Lamb; Taghi Manshouri; Jorge Cortes; Francis Giles; Anna Rogers; Maher Albitar
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.
Blood 2002;99(6):2265-7.
2002: Srdan Verstovsek; Andrew Lamb; Taghi Manshouri; Susan O'Brien; Stefan Faderl; Moshe Talpaz; Jorge Cortes; Maher Albitar
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
Cancer 2002;94(5):1517-21.
2001: Barbara Scappini; Francesco Onida; Hagop M Kantarjian; Li Dong; Srdan Verstovsek; Michael J Keating; Miloslav Beran
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3884-93.
2001: Srdan Verstovsek; Andrew Lamb; Alvaro Aguayo; Taghi Manshouri; Emil J Freireich; Michael Keating; Elihu Estey; Maher Albitar
Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome.
British journal of haematology 2001;114(2):290-5.
2001: Srdan Verstovsek; Andrew Lamb; Elihu Estey; Alvaro Aguayo; Francis Giles; Taghi Manshouri; Charles Koller; Zeev Estrov; Emil J Freireich; Michael Keating; Maher Albitar
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
Leukemia 2001;15(8):1165-70.
2001: Srdan Verstovsek; Elihu Estey; Taghi Manshouri; Michael Keating; Andrew Lamb; Francis Giles; Maher Albitar
High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
Leukemia & lymphoma 2001;42(3):511-6.